CO130 Subgroup Analysis of Quality-of-Life Outcomes in Patients Achieving F-VASI75: Pooled Results from Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo

Abstract

Vitiligo is a chronic autoimmune skin disease associated with quality-of-life (QoL) burden. Ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream demonstrated clinically meaningful repigmentation and was generally well tolerated in the 52-week TRuE-V1/TRuE-V2 phase 3 vitiligo studies. Pooled interim subgroup analyses of QoL outcomes are reported in patients who achieved the primary endpoint of ≥75% improvement in facial Vitiligo Area Scoring Index (F-VASI75), since QoL improvements often require a high degree of repigmentation in vitiligo.